MindWalk Holdings (HYFT) Free Cash Flow (2023 - 2026)
MindWalk Holdings (HYFT) posted quarterly Free Cash Flow of -$2.3 million for Q2 2026, down 39.33% year-over-year from -$3.8 million in Q2 2025, and down 9.91% quarter-over-quarter from -$2.1 million in Q1 2026.
Powered by 
Analysis
MindWalk Holdings (HYFT) Free Cash Flow (2023 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Free Cash Flow for 4 consecutive years, with -$2.3 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Free Cash Flow fell 39.33% year-over-year to -$2.3 million; the TTM figure through Apr 2026 stood at -$9.3 million (down 80.18% YoY), while the FY2026 annual figure was -$9.4 million, down 81.29% from the prior year.
- Free Cash Flow retreated to -$2.3 million in Q2 2026 per HYFT's latest filing, from -$2.1 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $207235.8 in Q4 2023 and bottomed at -$3.5 million in Q2 2023.
- Historically, Free Cash Flow has averaged -$1.7 million across 4 years, with a median of -$1.8 million in 2025.
- On a YoY basis, Free Cash Flow climbed as much as 63.81% in 2024 and fell as far as 869.97% in 2024.
- MindWalk Holdings' Free Cash Flow stood at $207235.8 in 2023, then plunged by 869.97% to -$1.6 million in 2024, then declined by 26.32% to -$2.0 million in 2025, then declined by 15.57% to -$2.3 million in 2026.
- Business Quant data shows HYFT's Free Cash Flow at -$2.3 million in Q2 2026, -$2.1 million in Q1 2026, and -$2.0 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -95.09 Mn |
| 10 | MindWalk Holdings | 61.69 Mn | 53.41 Mn | 1.82 Mn | -1.75 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | -1.75 Mn |
| Jan 31, 2026 | -2.12 Mn |
| Oct 31, 2025 | -2.02 Mn |
| Jul 31, 2025 | -2.86 Mn |
| Apr 30, 2025 | -548,831.11 |
| Jan 31, 2025 | -768,529.70 |
| Oct 31, 2024 | -1.60 Mn |
| Jul 31, 2024 | -1.14 Mn |
| Apr 30, 2024 | -334,834.21 |
| Jan 31, 2024 | -885,446.61 |
| Oct 31, 2023 | 207,235.78 |
| Jul 31, 2023 | -312,417.99 |
| Apr 30, 2023 | -1.31 Mn |
| Jan 31, 2023 | -1.28 Mn |